Baseline research biomarkers in patients by progression of CKD status
| Biomarkers . | Cystatin C–based CKD-EPI 2012 equation . | Creatinine-based CKD-EPI 2021 equation . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No progression of CKD . | Progression of CKD . | P value . | No progression of CKD . | Progression of CKD . | P value . | |||||
| N . | Median (Q1, Q3) . | N . | Median (Q1, Q3) . | N . | Median (Q1, Q3) . | N . | Median (Q1, Q3) . | |||
| Urinary AGT (ng/mg) | 95 | 5.45 (3.47, 9.99) | 18 | 8.03 (6.036, 14.5) | .015 | 109 | 5.9 (3.6, 9.95) | 6 | 18.6 (9.6, 26.2) | .018 |
| Soluble VACM-1 (ng/mL) | 131 | 1011.2 (833.5, 1271.5) | 23 | 1434.5 (1160.5, 1861.6) | <.0001 | 146 | 1039.8 (843.4, 1320.3) | 8 | 1792.12 (1317.0, 2173.4) | .007 |
| Urinary KIM-1 (ng/mg) | 95 | 0.63 (0.39, 0.98) | 17 | 0.70 (0.54, 0.81) | .37 | 107 | 0.63 (0.39, 0.94) | 5 | 1.21 (0.70, 1.63) | .08 |
| Urinary nephrin (ng/mg) | 89 | 28.1 (21.2, 37.6) | 12 | 29.5 (23.9, 33.9) | .74 | 99 | 28.3 (21.3, 37.2) | 4 | 33.8 (26.3, 38.7) | .64 |
| Biomarkers . | Cystatin C–based CKD-EPI 2012 equation . | Creatinine-based CKD-EPI 2021 equation . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No progression of CKD . | Progression of CKD . | P value . | No progression of CKD . | Progression of CKD . | P value . | |||||
| N . | Median (Q1, Q3) . | N . | Median (Q1, Q3) . | N . | Median (Q1, Q3) . | N . | Median (Q1, Q3) . | |||
| Urinary AGT (ng/mg) | 95 | 5.45 (3.47, 9.99) | 18 | 8.03 (6.036, 14.5) | .015 | 109 | 5.9 (3.6, 9.95) | 6 | 18.6 (9.6, 26.2) | .018 |
| Soluble VACM-1 (ng/mL) | 131 | 1011.2 (833.5, 1271.5) | 23 | 1434.5 (1160.5, 1861.6) | <.0001 | 146 | 1039.8 (843.4, 1320.3) | 8 | 1792.12 (1317.0, 2173.4) | .007 |
| Urinary KIM-1 (ng/mg) | 95 | 0.63 (0.39, 0.98) | 17 | 0.70 (0.54, 0.81) | .37 | 107 | 0.63 (0.39, 0.94) | 5 | 1.21 (0.70, 1.63) | .08 |
| Urinary nephrin (ng/mg) | 89 | 28.1 (21.2, 37.6) | 12 | 29.5 (23.9, 33.9) | .74 | 99 | 28.3 (21.3, 37.2) | 4 | 33.8 (26.3, 38.7) | .64 |
Progression of CKD based on decline in eGFR <60 mL/min per 1.73 m2 and with decline ≥25%.
Urine biomarkers (AGT, KIM-1, and nephrin) were normalized for urine creatinine.
P values are calculated from χ2 tests or Fisher exact tests if expected cell counts were small for comparing categorial characteristics and Wilcoxon-Mann-Whitney tests for comparing continuous characteristics across strata.